![SpringWorks on X: "We are happy to have initiated the rolling submission of our New Drug Application with the FDA for our investigational MEK inhibitor in pediatric and adult patients with neurofibromatosis SpringWorks on X: "We are happy to have initiated the rolling submission of our New Drug Application with the FDA for our investigational MEK inhibitor in pediatric and adult patients with neurofibromatosis](https://pbs.twimg.com/media/GH0wd0IWYAAxrvW.jpg:large)
SpringWorks on X: "We are happy to have initiated the rolling submission of our New Drug Application with the FDA for our investigational MEK inhibitor in pediatric and adult patients with neurofibromatosis
![Pfizer Inc. on X: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older. Pfizer Inc. on X: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older.](https://pbs.twimg.com/media/E0x-tDpXIAIIv4g.jpg)
Pfizer Inc. on X: "BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older.
![Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line | Fierce Biotech Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line | Fierce Biotech](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1617619190/Genscript%20Legend%20Biotech.png/Genscript%20Legend%20Biotech.png?VersionId=pIdRexRCwiJRh5G7QiMCLwqnyRuSj8Cm)
Legend Biotech, J&J finish off rolling submission for CAR-T hopeful, approach finish line | Fierce Biotech
![Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne](https://cureduchenne.org/wp-content/uploads/2022/10/SYNTHERA-2WEB-POST-HEADER.png)
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy - CureDuchenne
![FA Research Alliance on X: "Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia Click here to read the full press release: FA Research Alliance on X: "Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia Click here to read the full press release:](https://pbs.twimg.com/media/FPNYyzKXIAkVYEA.jpg)
FA Research Alliance on X: "Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia Click here to read the full press release:
![Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines - Clarivate Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines - Clarivate](https://clarivate.com/wp-content/uploads/2022/07/Median-submission-lag-and-roll-out-times-for-anti-cancer-and-immunomodulator-NASs-approved-via-Project-Orbis-between-2019-2021-1024x602.jpg)
Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines - Clarivate
![Verastem (VSTM): Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib | Seeking Alpha Verastem (VSTM): Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib | Seeking Alpha](https://media.gettyimages.com/id/1646509054/photo/female-lab-director-smiles-as-male-colleague-reports-experiment-results.jpg?b=1&s=170667a&w=0&k=20&c=ZI4c84PPKDYobA-I1mpkezUEmmJ_YqhOl4C1oKaUbns=)